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Purpose: Although the applications of adipose tissue-derived cells (ADCs) in re-
generative medicine have been investigated, the role of ADCs in fracture healing 
remains unclear. In this study, we examined the fracture-healing effects and survival 
of transplanted ADCs using micro-computed tomography (CT) and biolumines-
cence imaging (BLI). Materials and Methods: Luciferase-expressing ADCs were 
suspended in solubilized basement membrane preparation (SBMP) and xenografted 
on defects in the right femur of nude mice (n=5). SBMP alone was grafted on a de-
fect in the contralateral femur. Serial in vivo micro-CT and BLI were performed for 
20 days. Ex vivo BLI images of both femurs were obtained. Differences in the Houn-
sfield unit (HU), HUratio, and luciferase activities were compared using Wilcoxon 
signed-rank tests and non-parametric longitudinal analyses (p<0.05). Results: In 
vivo BLI revealed a signal drop on day 2, reconstitution on day 5, and continuous 
decrement thereafter. Ex vivo BLI revealed residual activity in the ADC-implanted 
and adjacent areas. No activity was detected in the contralateral femur. The overall 
increment rate of normalized HUs was higher for ADC-treated femurs than for 
SBMP-treated femurs. Cell migration to distant injury sites was not detected. Con-
clusion: Enhanced bone density in the implant area suggests that ADCs have frac-
ture-healing effects.
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INTRODUCTION
Despite substantial advances in the field of orthopedics and related medicine, 
5‒10% of fractures that occur annually in the United States end in non-union.1 
Fracture healing is a complex process that is orchestrated by numerous factors, in-
cluding cytokines, chemokines, osteoblasts, osteoclasts, fibroblasts, and inflamma-
tory cells.2,3 Mesenchymal stem cells (MSCs) have been studied extensively for 
their ability to accelerate bone regeneration and healing.4,5 MSCs occur in various 
tissues, including bone marrow, adipose tissue, periosteum, fetal blood, and synovi-
um.6-8 Although bone marrow-derived MSCs (BMMSCs) have been widely stud-
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minced for 5 min. The tissues were then digested with 0.075% 
collagenase (Sigma-Aldrich, St. Louis, MO, USA) at 37°C 
for 1 h. Neutralized cells were centrifuged, and mature adi-
pocytes and fibro-vascular fractions were discarded. Pelleted 
stromal cells were then passed through a 100-μm cell strainer 
before plating. The cells were cultured in Dulbecco’s modi-
fied Eagle medium, containing 10% fetal bovine serum, 100 
IU/mL penicillin, 100 IU/mL streptomycin, and 0.25 µg/mL 
amphotericin at 37°C in an atmosphere of 5% CO2. The pas-
sage of ADCs used in this study was 2 or 3. A preliminary in 
vitro BLI of cultured ADCs was performed to confirm lu-
ciferase expression before implantation into animal models.
Surgery and local administration of ADC in the 
fracture model
Five nude mice (NU/NU), aged 8‒10 weeks, were purchased 
from the Charles River Laboratory (Wilmington, MA, USA). 
The animals were placed in a supine position and adminis-
tered isoflurane (an inhalational anesthetic). A surgical inci-
sion was made along the lateral side of the bilateral thighs 
to expose the femoral shafts. A hole with 0.5 mm diameter 
was drilled in the femora using a small trephine bit, under sa-
line irrigation.
The harvested reporter-expressing ADCs (6×105) were 
suspended in solubilized basement membrane preparation 
(SBMP) (MatrigelTM, BD Biosciences, San Jose, CA, USA) 
and inserted into the hole in the right femur shaft. Subse-
quently, the muscles and skin were sutured. In addition, SB-
MP alone was administered into a hole of the same size in 
the contralateral femur, using the same protocol.
In vivo and ex vivo BLI
Approximately 3 mg of luciferin (30 mg/mL solution of D-
luciferin; Biosynth International, IL, USA) was adminis-
tered via intraperitoneal injection. BLI was performed 10 
min after the administration of luciferin using a cooled 
charge-coupled device camera (IVIS; Xenogen, CA, USA). 
The acquisition time was 5 min, and five mice were imaged 
simultaneously in the prone and bilateral decubitus posi-
tions. BLI was performed on days 0, 2, 5, 7, 9, 12, 14, 16, 
and 20 after the operation and administration of ADCs. All 
BLI data from mice with implanted ADC were obtained 
from left decubitus images. The BLI data were quantified by 
drawing a 3.0-cm sized region of interest (ROI) to include 
the entire BLI signal detected on day 0. An ROI of the same 
size was used to measure BLI signals during the follow-up 
period to avoid loss of BLI activity from the areas near the 
ied, these cells have limited applications in fracture healing 
owing to low yields and invasive harvesting procedures.9 On 
the other hand, adipose tissue might be an ideal source of 
MSCs because of its abundance in the body. In addition, 
adipose tissue-derived MSCs (ADMSCs) may be easily har-
vested. Therefore, ADMSCs are being studied extensively for 
potential applications in the field of stem cell therapeutics.7,10
MSCs from diverse tissues and organs have been introduc-
ed via systemic or local routes to treat fractures. Many stud-
ies have demonstrated that systemically introduced BMMSCs 
and ADMSCs migrate to the fracture site and promote bone 
healing.11-14 However, other studies showed that only genet-
ically modified cells that expressed bone morphogenic pro-
tein-2 had significant bone regeneration effects, while AD-
MSCs alone failed to promote bone healing.10,15 Therefore, 
the exact role of MSCs in fracture healing remains contro-
versial and requires further investigation.
Recent advances in imaging technologies such as micro-
computed tomography (CT) have made it possible to assess 
the healing process of the skeletal system by measuring the 
Hounsfield unit (HU) of bone tissue. Bioluminescence im-
aging (BLI) has enabled us to monitor viable grafted cells 
expressing genetically engineered reporter genes such as 
green fluorescent protein (GFP) and luciferase.14 In our study, 
we harvested adipose tissue derived cells (ADCs) of trans-
genic mice and achieved stable levels of luciferase activity 
without degradation during the entire follow-up period.
The main purpose of this study was to evaluate the bone-
healing effects and survival or proliferation rates of locally 
administered ADCs during the early phase of fracture heal-
ing. In addition, we attempted to evaluate the trafficking abil-
ity of locally administered ADCs to remote fracture sites us-
ing micro-CT and BLI. 
MATERIALS AND METHODS
Mesenchymal stem cells isolation and culture
All experiments were approved by the Institutional animal 
care and use committee of the Stanford University. To obtain 
steady reporter gene signals, we isolated ADCs from trans-
genic mice carrying the β-actin promoter gene and express-
ing GFP and firefly luciferase, instead of transfecting report-
er genes into harvested ADCs. Subcutaneous adipose tissue 
was obtained from the region between the lower anterior ab-
dominal wall and the inguinal area of transgenic mice, wash-
ed in phosphate buffered saline several times, and finely 
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was evaluated by measuring the HU of the bone in a 0.2285 
mm3-sized cylindrical volume of interest (VOI). The HU 
data obtained from the VOIs of bilateral femoral holes were 
plotted versus time. To minimize bias due to differences in 
the initial baseline HUs between the control and ADC-treated 
sites, we used another parameter, the HUratio. The HUratio was 
calculated by dividing the HU at each time point with the 
baseline HU. The HUs and HUratio of both the left and right 
femurs during the follow-up period were compared to eval-
uate the bone-healing effects of ADCs. 
Statistical analysis
Statistical differences in the BLI signals during the follow-
up period were assessed using the Mann-Whitney U test. 
The HUs and HUratio of the ADC- and SBMP-treated (con-
trol) sites were compared and evaluated using the Wilcoxon 
signed-rank test. To analyze whether the differences be-
tween the HUratio of the SBMP- and ADC-treated sites in-
creased significantly at each time point, a non-parametric 
longitudinal analysis was performed. Differences were con-
sidered statistically significant if p<0.05. All statistical eval-
uations were performed using the SAS statistical software 
(version 9.2; SAS Institute Inc., Cary, NC, USA).
hole in the femur (Fig. 1). A time versus activity curve was 
obtained from this data to evaluate changes in luciferase ac-
tivity with time. Bioluminescence activity was expressed in 
terms of average radiance (photon/cm2/s/steradian).
After the last CT follow-up, the animals were adminis-
tered an intraperitoneal injection of D-luciferin and sacrificed 
after 10 min. ADC-treated and control femora were har-
vested, and the soft tissue overlying the femoral defect was 
excised. BLI data wererecorded for the bones, with the en-
trance to the hole facing the camera.
 
Micro-CT
CT images of both femurs were obtained using a dedicated 
small animal CT scanner (eXplore RS micro-CT system, 
GE Medical Systems, Raleigh, NC, USA). The animals 
were placed on the scanner table in a prone position under 
inhalation anesthesia and exposed to a cone beam (80 kVp, 
450 µA) for 400 ms. Image acquisition and reconstruction 
were performed using the eXplore Evolver and eXplore Re-
construction Interface software, respectively. Micro-CT im-
ages were obtained on days 0, 3, 5, 7, 12, 14, 16, and 20 after 
the operation and implantation of ADCs. The resolution of 
the reconstructed image (voxel) was 0.45×0.45×0.45 mm3 
(Fig. 2). The change in bone density in the femoral defect 
Fig. 1. Bioluminescence imaging of adipose tissue-derived cell-implanted fracture model. A region of interest (ROI) that included nearly the entire signal was 
drawn on the image recorded in the left lateral decubitus position.
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To determine whether the locally administered ADCs mi-
grated to remote fracture sites, serial in vivo and ex vivo BLI 
were performed. No bioluminescence activity was detected 
in the left femur (control side) in both the ex vivo and in vivo 
studies, although ex vivo BLI of the right femora of all five 
mice showed persistent luciferase activities to various de-
RESULTS
 
Second or third passage ADCs harvested from transgenic 
mice expressing two reporter genes–GFP and firefly lucif-
erase–showed relevant bioluminescence activities in a pre-
liminary in vitro BLI. Post transplantation, initial in vivo BLI 
of the five femur fracture models revealed strong biolumi-
nescence activities; however, an abrupt decrease in activity 
was noted on day 2, followed by an increase on day 5. How-
ever, the Mann-Whitney U test showed no significant differ-
ences in the activities between days 0 and 5 (p=0.841). After 
day 5, bioluminescence activity decreased continuously with 
time. However, the time versus activity curve revealed a rela-
tively rapid decrease in the activity until day 9 and a slow 
decrease thereafter, until day 14. This was followed by a st-
eady level of activity in the remaining 6 days (Fig. 3). There 
were no significant differences in the bioluminescence ac-
tivities between days 9 and 20. During the follow-up period, 
no significant increase in the BLI signal could be detected, 
which might be indicative of proliferation of implanted 
ADCs.
Fig. 2. Micro-computed tomography (CT) of bilateral femurs with holes (diameter, 0.5 mm). Baseline micro-CT images of control (A) and adipose tissue-de-
rived cell (ADC)-implanted sides (B) showed relatively low bone densities in the holes. Final micro-CT images on day 20 showed increased bone densities in 
both the control (C) and ADC-implanted sides (D).
A
C
B
D
Fig. 3. The time vs. activity curve for firefly luciferase-expressing ADCs 
showed rapid decrement on post-operative day (POD) 7, followed by slow 
decrement until POD 12, before reaching a plateau. BLI, bioluminescence 
imaging; ADCs, adipose tissue-derived cells. 
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Micro-CT imaging of the femoral holes revealed higher 
HU values for the SBMP-treated side than for the ADC-tr-
eated side from baseline to day 16; serial HUs increased ste-
adily with time. However, there was no significant difference 
in the HUs between the two sides at each time point (Fig. 
5A). The addition of the ADC pellet to SBMP may have in-
creased the semi-liquid volume of the injectate in the ADC-
SBMP group, compared with the SBMP-only group. This 
increased liquid volume might have washed away the he-
matoma and calcifications in the bone defect, resulting in a 
lower HU on the ADC-treated side. Therefore, to minimize 
bias caused by the difference in baseline HUs between the 
two groups, HUratio, which represents the relative change of 
HUs at follow-up time points with respect to baseline HUs, 
was calculated and compared in the same manner. The HUratio 
graph revealed an increasing difference in the HUratio between 
the two groups (Fig. 5B), and a higher increment ratio in 
the ADC-treated group than in the control group. We also 
compared the differences between the HUratio of the two 
groups (inter-group gap) on days 16 and 20. The gap on day 
20 was significantly larger than that on day 16 and earlier 
time points. These results were confirmed by performing a 
non-parametric longitudinal analysis (p<0.001). These re-
sults imply that the ADC-treated side showed accelerated 
bone healing with time.
DISCUSSION
 
Although fractures are fairly common, treatment is not al-
ways successful because of various factors such as injuries 
to surrounding soft tissues, poor blood supply, and osteopo-
rosis.16 Therefore, fracture treatment in complicated cases 
such as in the elderly and in patients of osteoporosis and im-
mune suppression, has been difficult despite advances in 
surgery and regenerative medicine.2 Among the various 
new therapeutic approaches that have been proposed for the 
treatment of fractures, stem cells are promising candidates 
that activate bone healing. In particular, MSCs are known 
to be involved in the bone healing process. It has been sug-
gested that MSCs are recruited to the injury site, where they 
proliferate and differentiate into osteoblasts.5 Initially, most 
studies investigated the bone-healing properties of BM-
MSCs. However, these cells have limited applications as 
therapeutic agents because of their invasive harvesting pro-
cedures and relatively low yields.17 Therefore, ADMSCs 
were investigated as an alternative to BMMSCs owing to 
grees. In two mice, the focal luciferase signal was confined 
to the hole in the femur; however, in the other three mice, the 
BLI signal could be detected in the femoral hole as well as 
the adjacent femoral shaft (Fig. 4).
Fig. 4. Ex vivo BLI revealed no luciferase activity in the left femur. However, 
in three out of five mice, luciferase activity was detected in the primary site 
on the right femur as well as in adjacent areas (A, C, and D), while in the re-
maining two, activity was detected only in the primary sites (B and E). BLI, 
bioluminescence imaging.
A
E
D
B
C
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Many studies have reported that transplanted stem cells 
proliferate, differentiate into osteoblasts, and promote bone 
healing. In our study, however, in vivo BLI showed no evi-
dence of proliferation of ADCs in the implant site.19 There-
fore, the healing effect of locally administered ADCs may 
be attributed to cytokine production and humoral effects, 
rather than direct cellular proliferation and differentiation 
into osteoblasts and stromal cells. However, ex vivo BLI re-
vealed persistent signals in the implanted area, albeit slight-
ly lower than that in the initial phase, suggesting that ADCs 
do survive in the fracture site and promote fracture healing. 
It is possible that the implanted cells proliferate and survive 
for longer periods, but the signal may have been lost be-
cause of the limited optical penetration of bioluminescence 
signal through scarred soft tissue. Further investigations are 
required to confirm this hypothesis. 
Because our previous study revealed trafficking of intra-
venously administered stem cells to fracture sites, we inves-
tigated the trafficking ability of transplanted ADCs to a re-
mote injury area i.e., the hole in the contralateral femur. The 
results revealed that there was no detectable signal in the left 
femur, as assessed by ex vivo and in vivo BLI. Ex vivo imag-
es revealed luciferase activities in relatively distant areas on 
the right femur in addition to areas near the ADC-implanted 
hole. This might be attributed to SBMP-assisted cell prolif-
eration. In addition, it is possible that locally administered 
ADCs behave differently in vivo, and might be able to mi-
grate to nearby areas through blood capillaries. The time ver-
their abundance and easy harvesting procedures.18 However, 
the therapeutic potential of ADMSCs for treating fractures 
has not been studied extensively.
Recently, advanced imaging techniques such as BLI and 
micro-CT have made it possible to serially monitor implant-
ed MSCs and changes in bone density without the need to 
sacrifice the animals. In our study, we used ADCs harvested 
from transgenic mice carrying a ubiquitous promoter gene 
to avoid low yield of reporter gene upon transfection using 
lipofectamine or lentivirus. Consequently, we could precise-
ly evaluate the survival and proliferative behavior of impl-
anted MSCs in a living animal model. BLI in the early phase 
of follow-up revealed a rapid drop in cell population on day 
2, and subsequent reconstitution on day 5. This result was 
similar to that obtained in our previous study involving the 
systemic injection of reporter ADCs in fracture models, wh-
ere the signal dropped 3 days after intravenous injection, in-
creased on day 6, and then decreased to a plateau thereaf-
ter.14 These results suggest that the stem cells undergo rapid 
cell demise in the initial hostile environment around the fr-
acture, followed by a brief surge, and a gradual decline th-
ereafter. This result also suggests that too many cells cannot 
survive in the targeted fracture area, and an appropriate 
number of cells must be transplanted in each case to ensure 
survival. Shoji, et al.9 reported successful treatment of frac-
ture with ADMSCs using a dosage equal to one sixth of the 
dose used in our study. Further studies are necessary to op-
timize the dosage of ADMSCs. 
Fig. 5. (A) There was no significant difference in the Hounsfield units (HUs) of the right and left femurs until day 20. (B) However, there was a significant dif-
ference in the HUratio (normalized to the baseline values) of the right and left femurs on day 20. POD, post-operative day; ADC, adipose tissue-deriviced cell.
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improvements in the sensitivity of BLI and reporter gene 
technology might enable the monitoring of locally adminis-
tered ADCs for longer time intervals.
In summary, BLI data revealed that the levels of locally 
administered ADCs fluctuated in the early postoperative 
phase and reached a plateau thereafter, without providing 
definite evidence of cell proliferation or migration to remote 
sites of injury. Despite the relatively short follow-up period, 
micro-CT revealed that the implanted ADCs enhanced the 
rate of fracture healing during the study period, as suggested 
by the incremental patterns of the HUs and HUratio. Our re-
sults suggest that ADCs play a role in fracture healing; this ef-
fect might be mediated by cytokines or other humoral effects. 
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